BR9610390A - O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i - Google Patents

O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Info

Publication number
BR9610390A
BR9610390A BR9610390A BR9610390A BR9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A
Authority
BR
Brazil
Prior art keywords
pct
thienotriazolodiazepine
apoliprotein
increase levels
sec
Prior art date
Application number
BR9610390A
Other languages
English (en)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9610390A publication Critical patent/BR9610390A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9610390A 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i BR9610390A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
BR9610390A true BR9610390A (pt) 1999-07-06

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610390A BR9610390A (pt) 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Country Status (14)

Country Link
US (1) US5854238A (pt)
EP (1) EP0853480B1 (pt)
JP (1) JPH11512107A (pt)
KR (1) KR19990044460A (pt)
CN (1) CN1101680C (pt)
AT (1) ATE230600T1 (pt)
AU (1) AU725249B2 (pt)
BR (1) BR9610390A (pt)
CA (1) CA2230477A1 (pt)
DE (1) DE69625696T2 (pt)
DK (1) DK0853480T3 (pt)
ES (1) ES2188783T3 (pt)
TR (1) TR199800406T1 (pt)
WO (1) WO1997009048A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP1426046A4 (en) 2001-09-14 2005-11-02 Shionogi & Co NEW USE OF TRICYCLIC COMPOUNDS
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
JP5490811B2 (ja) * 2008-10-30 2014-05-14 スルコメッド エルエルシー アポａに対して活性なチエノトリアゾロジアゼピン誘導体
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
CA2799420C (en) 2010-05-14 2018-10-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 白血病を治療するための組成物および方法
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
KR20170032473A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디아제판 유도체 및 그의 용도
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
AU2016319785C1 (en) 2015-09-11 2021-04-01 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
EP3380100A4 (en) 2015-11-25 2019-10-02 Dana-Farber Cancer Institute, Inc. BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF
EP3806860A1 (en) 2018-06-13 2021-04-21 Dybly AG Preparation of condensed triazepine derivatives and their use as bet inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (pt) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
EP0853480B1 (en) 2003-01-08
JPH11512107A (ja) 1999-10-19
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
MX9801753A (es) 1998-08-30
DE69625696D1 (de) 2003-02-13
AU725249B2 (en) 2000-10-12
CN1195989A (zh) 1998-10-14
DK0853480T3 (da) 2003-05-05
TR199800406T1 (en) 1998-05-21
US5854238A (en) 1998-12-29
KR19990044460A (ko) 1999-06-25
EP0853480A1 (en) 1998-07-22
ATE230600T1 (de) 2003-01-15
DE69625696T2 (de) 2003-10-16
CN1101680C (zh) 2003-02-19
AU6930396A (en) 1997-03-27
CA2230477A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
BR9610390A (pt) O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
FI945363A (fi) Uusia merkaptoasetyyliamidopyridatso (1,2)pyridatsiini-, pyratsolo(1,2)pyridatsiini-, pyridatso (1,2-a)(1,2)diatsepiini- ja pyratsolo(1,2-a)(1,2)diatsepiinijohdannaisia, jotka ovat käyttökelpoisia enkefalisaasin ja ACE:n estäjinä
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
BR9813508A (pt) Inibição de replicação viral associada com membrana
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
NO980296D0 (no) Forbedrede terapeutiske midler
NO975028L (no) Piperazinoderivater som neurokininantagonister
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE169922T1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
SE9301831D0 (sv) Pharmaceutical compositions
ATE223427T1 (de) Modifizierte kojibioside analoge
AR005866A1 (es) Composicion farmaceutica antioxidante
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
AU675281B2 (en) Application of riluzole as a radiorestorer
BR9704686A (pt) Grupos de bactérias e composição farmacêutica contendo tais grupos, e uso da mesma para impedir e tratar doenças associadas com, ou causadas pelo metabolismo alterado de ácido de bìlis.

Legal Events

Date Code Title Description
HHB Publication of an application: rectification
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRENTE PEDIDO, COM BASE NOS ARTIGOS 8 E 11 DA LPI E DADO COM CONCLUIDO O EXAME.